4
Views
2
CrossRef citations to date
0
Altmetric
Original Article

The regulation of quinolinic acid in human immunodeficiency virus-infected monocytes

, , , , &
Pages 111-117 | Received 13 Dec 1995, Accepted 23 Feb 1996, Published online: 10 Jul 2009
 

Abstract

Quinolinic acid (Quia) is thought to underlie cognitive and motor dysfunctions for a variety of neurological disorders. Specifically, in human immunodeficiency virus (HTV)-associated dementia, Quin levels correlate with the degree of neurological dysfunction observed in affected individuals. Since recent data from our laboratories suggest that both HIV-1 infection and activation of brain macrophages are required for the development of neurotoxicity we examined Quin production during virus infection and immune activation. HTV-1 infection of monocytes induced low levels of Quin while lipopolysaccharide (LPS) or interferon-gamma (IFN-γ) activation of the virus-infected cells elicited 10-fold higher levels. The combined effects of LPS and IFN-γ for Quin production in HIV-infected monocytes was identical to each factor added alone. Little or no Quin was detected in unstimulated uninfected monocytes. LPS or IFN-γ activation of uninfected monocytes produced substantially higher levels of Quin than found in similarly stimulated HIV-1-infected monocytes. These results were at variance to the production of tumor necrosis factor-alpha (TNF-α). Here, a 2- to 5-fold increase in TNF-α levels were observed in culture fluids of LPS-activated HIV-infected cells when compared to similarly stimulated uninfected monocytes. The effect of LPS-induced Quin production by HIV-infected monocytes was not altered by primary human astrocytes. These data suggest that Quin levels seen in HTV dementia are a reflection of macrophage/microglial activation seen during advanced clinical disease. These findings could help explain, in part, why few HTV-1-infected brain macrophages can give rise to significant neurological impairments.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.